Hodgkin lymphoma : nature.com subject feeds
Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years
Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors
Tyramide-conjugated DNA barcodes enable signal amplification for multiparametric CODEX imaging
The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity
The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years
3D analyses reveal T cells with activated nuclear features in T-cell/histiocyte-rich large B-cell lymphoma
Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter£
Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma
Maximum-tolerated dose of lomustine used in combination with etoposide and cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patients
Author Correction: Hodgkin lymphoma
Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP
Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas
Conditional relative survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma in the Netherlands
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma
CAR T cells are active in Hodgkin lymphoma
Hodgkin lymphoma
Can we cure refractory Hodgkin’s lymphoma with transplantation£
Tumor-associated macrophages in classical Hodgkin lymphoma: hormetic relationship to outcome
Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989–2017
Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT
Autologous hematopoietic cell transplantation for the treatment of relapsed/refractory pediatric, adolescent, and young adult Hodgkin lymphoma: a single institutional experience
PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma
Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities
Precise detection of genomic imbalances at single-cell resolution reveals intra-patient heterogeneity in Hodgkin’s lymphoma
Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Feed Fetched by RSS Dog.